SCLP vs. PRTC, OXB, HZD, FARN, VRP, ARIX, CIR, 4BB, BVXP, and AVCT
Should you be buying Scancell stock or one of its competitors? The main competitors of Scancell include PureTech Health (PRTC), Oxford Biomedica (OXB), Horizon Discovery Group plc (HZD.L) (HZD), Faron Pharmaceuticals Oy (FARN), Verona Pharma plc (VRP.L) (VRP), Arix Bioscience (ARIX), Circassia Group (CIR), 4basebio (4BB), Bioventix (BVXP), and Avacta Group (AVCT). These companies are all part of the "biotechnology" industry.
Scancell vs.
PureTech Health (LON:PRTC) and Scancell (LON:SCLP) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, valuation, earnings, dividends, risk, media sentiment, profitability, analyst recommendations and institutional ownership.
PureTech Health received 343 more outperform votes than Scancell when rated by MarketBeat users. Likewise, 86.60% of users gave PureTech Health an outperform vote while only 74.50% of users gave Scancell an outperform vote.
PureTech Health currently has a consensus target price of GBX 455, suggesting a potential upside of 252.71%. Given PureTech Health's stronger consensus rating and higher probable upside, equities analysts plainly believe PureTech Health is more favorable than Scancell.
Scancell has a net margin of 0.00% compared to PureTech Health's net margin of -17,620.94%. Scancell's return on equity of 98.74% beat PureTech Health's return on equity.
79.9% of PureTech Health shares are owned by institutional investors. Comparatively, 46.5% of Scancell shares are owned by institutional investors. 15.9% of PureTech Health shares are owned by company insiders. Comparatively, 5.0% of Scancell shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
In the previous week, Scancell had 1 more articles in the media than PureTech Health. MarketBeat recorded 1 mentions for Scancell and 0 mentions for PureTech Health. PureTech Health's average media sentiment score of 1.11 beat Scancell's score of 0.86 indicating that PureTech Health is being referred to more favorably in the media.
Scancell has lower revenue, but higher earnings than PureTech Health. Scancell is trading at a lower price-to-earnings ratio than PureTech Health, indicating that it is currently the more affordable of the two stocks.
PureTech Health has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500. Comparatively, Scancell has a beta of 0.35, suggesting that its share price is 65% less volatile than the S&P 500.
Summary
PureTech Health beats Scancell on 12 of the 17 factors compared between the two stocks.
Get Scancell News Delivered to You Automatically
Sign up to receive the latest news and ratings for SCLP and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Scancell Competitors List
Related Companies and Tools
This page (LON:SCLP) was last updated on 5/2/2025 by MarketBeat.com Staff
Buy SCLP Stock Free SCLP Stock Alerts